Clinical Trials Finder

Independent ClinicalTrials.gov directory

Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 12:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Part 1 Clear all

Completed Phase 1 Interventional Accepts healthy volunteers

Fruquintinib CYP3A Inhibitor and Inducer Study

NCT04557397

View directory record Official record

Conditions: Drug Drug Interaction
Interventions: Fruquintinib, Itraconazole, Rifampin; Drug
Lead sponsor: Hutchison Medipharma Limited; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Cypress, California

Source: ClinicalTrials.gov public record

Updated Jun 17, 2021 · Synced May 22, 2026, 12:43 AM EDT

Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects

NCT03669614

View directory record Official record

Conditions: Cystic Fibrosis
Interventions: Inhaled AR-501, Inhaled Placebo; Drug
Lead sponsor: Aridis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 49 Years

Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 25
States / cities: Tucson, Arizona • Long Beach, California • Denver, Colorado + 22 more

Source: ClinicalTrials.gov public record

Updated Mar 8, 2023 · Synced May 22, 2026, 12:43 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study of [14C]-LY3866288 in Healthy Participants

NCT06644378

View directory record Official record

Conditions: Healthy
Interventions: [14C]-LY3866288, LY3866288; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Source: ClinicalTrials.gov public record

Updated Jan 21, 2025 · Synced May 22, 2026, 12:43 AM EDT

Completed Not applicable Interventional Accepts healthy volunteers

Tailoring of Vaccine-Focused Messages: Moral Foundations

NCT02851459

View directory record Official record

Conditions: Childhood Vaccinations
Interventions: Baseline Survey, Pre-intervention Survey, Morally Congruent Message, Morally Non-Congruent Message, Control Message, Post-Intervention Survey; Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 50 Years

Enrollment: 850 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Source: ClinicalTrials.gov public record

Updated Mar 9, 2017 · Synced May 22, 2026, 12:43 AM EDT

Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants

NCT06576271

View directory record Official record

Conditions: Systemic Lupus Erythematosus
Interventions: GSK4527363, Placebo matching GSK4527363, Belimumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 142 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: Scottsdale, Arizona • Aurora, Colorado • Las Vegas, Nevada + 3 more

Source: ClinicalTrials.gov public record

Updated Apr 28, 2026 · Synced May 22, 2026, 12:43 AM EDT

Completed Phase 1 Interventional

Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer

NCT04666129

View directory record Official record

Conditions: Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer
Interventions: Relugolix, Abiraterone, Prednisone, Methylprednisolone, Apalutamide, Docetaxel; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older · Male only

Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 16
States / cities: Tucson, Arizona • Little Rock, Arkansas • Lakewood, Colorado + 13 more

Source: ClinicalTrials.gov public record

Updated Aug 16, 2025 · Synced May 22, 2026, 12:43 AM EDT

Completed Phase 1 Interventional

A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

NCT00478634

View directory record Official record

Conditions: Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumors, Neoplasms, Colorectal
Interventions: RAD001, Cetuximab, Irinotecan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 16
States / cities: Fayetteville, Arkansas • Bakersfield, California • La Jolla, California + 13 more

Source: ClinicalTrials.gov public record

Updated Nov 1, 2012 · Synced May 22, 2026, 12:43 AM EDT

Terminated Phase 1Phase 2 Interventional Results available

An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus

NCT01701063

View directory record Official record

Conditions: Hepatitis C
Interventions: Telaprevir, Peginterferon alfa-2b, Ribavirin; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 3 Years to 17 Years

Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 13
States / cities: Phoenix, Arizona • San Francisco, California • Denver, Colorado + 10 more

Source: ClinicalTrials.gov public record

Updated Jul 19, 2016 · Synced May 22, 2026, 12:43 AM EDT

Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia

NCT04659863

View directory record Official record

Conditions: Familial Hypercholesterolemia - Homozygous
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 17 Years

Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boca Raton, Florida

Source: ClinicalTrials.gov public record

Updated Jan 12, 2026 · Synced May 22, 2026, 12:43 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of the Effects of Itraconazole and Rifampin on LOXO-305 in Healthy Participants

NCT05134337

View directory record Official record

Conditions: Healthy Volunteers
Interventions: LOXO-305, Itraconazole, Rifampin; Drug
Lead sponsor: Loxo Oncology, Inc.; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Daytona Beach, Florida

Source: ClinicalTrials.gov public record

Updated Jan 8, 2025 · Synced May 22, 2026, 12:43 AM EDT

Terminated Phase 1 Interventional Results available

Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)

NCT00486265

View directory record Official record

Conditions: Acute Myelogenous Leukemia
Interventions: AZD4877; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older

Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 3
States / cities: Chicago, Illinois • Houston, Texas • San Antonio, Texas

Source: ClinicalTrials.gov public record

Updated Dec 20, 2010 · Synced May 22, 2026, 12:43 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Bioavailability of Fedratinib When Administered in Different Ways to Healthy Adult Participants

NCT05051553

View directory record Official record

Conditions: Healthy Volunteers
Interventions: Fedratinib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Source: ClinicalTrials.gov public record

Updated Jun 26, 2022 · Synced May 22, 2026, 12:43 AM EDT

Not listed Phase 1Phase 2 Interventional

Tolerability and Efficacy of RJX in Patients With COVID-19

NCT04708340

View directory record Official record

Conditions: COVID-19, Acute Respiratory Distress Syndrome, SARS-CoV-2, Hypoxemia
Interventions: Rejuveinix (RJX) Active Comparator, Placebo Comparator; Drug
Lead sponsor: Reven Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 237 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Houston, Texas • New Braunfels, Texas

Source: ClinicalTrials.gov public record

Updated Mar 14, 2022 · Synced May 22, 2026, 12:43 AM EDT

Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy Adults

NCT07597928

View directory record Official record

Conditions: Healthy Adults, Healthy
Interventions: PF-08049820, Rabeprazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older

Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Source: ClinicalTrials.gov public record

Updated May 19, 2026 · Synced May 22, 2026, 12:43 AM EDT

Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study of TAK-951 in Healthy Adults

NCT06610279

View directory record Official record

Conditions: Healthy Volunteers
Interventions: TAK-951, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Lenexa, Kansas • Salt Lake City, Utah

Source: ClinicalTrials.gov public record

Updated Nov 21, 2024 · Synced May 22, 2026, 12:43 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants

NCT04844424

View directory record Official record

Conditions: Healthy
Interventions: Milvexian; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Salt Lake City, Utah

Source: ClinicalTrials.gov public record

Updated May 22, 2025 · Synced May 22, 2026, 12:43 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants

NCT06417229

View directory record Official record

Conditions: Healthy Participants
Interventions: BMS-986365, Rabeprazole; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 60 Years · Male only

Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Lenexa, Kansas

Source: ClinicalTrials.gov public record

Updated Mar 5, 2025 · Synced May 22, 2026, 12:43 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, 2-Part, Single Ascending Dose Assessment of the Safety, Tolerability, and Pharmacokinetics of Rolapitant Intravenous in Healthy Volunteers

NCT02382666

View directory record Official record

Conditions: Chemotherapy-induced Nausea and Vomiting
Interventions: Rolapitant; Drug
Lead sponsor: Tesaro, Inc.; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Source: ClinicalTrials.gov public record

Updated Aug 24, 2015 · Synced May 22, 2026, 12:43 AM EDT

Active, not recruiting Phase 3 Interventional

Atacicept in Subjects With IgA Nephropathy

NCT04716231

View directory record Official record

Conditions: IgA Nephropathy, Berger Disease
Interventions: Atacicept, Placebo to match Atacicept; Biological · Other
Lead sponsor: Vera Therapeutics, Inc.; Industry
Eligibility: 18 Years and older

Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Brisbane, California

Source: ClinicalTrials.gov public record

Updated Sep 29, 2025 · Synced May 22, 2026, 12:43 AM EDT

Recruiting Phase 3 Interventional

Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia

NCT06597006

View directory record Official record

Conditions: Familial Hypercholesterolemia - Homozygous
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 11 Years

Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: San Francisco, California • Washington D.C., District of Columbia • St Louis, Missouri

Source: ClinicalTrials.gov public record

Updated Feb 19, 2026 · Synced May 22, 2026, 12:43 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

3-part Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Multiple Doses of CC-220 and Relative Bioavailability of a Formulated CC-220 Capsule

NCT02034773

View directory record Official record

Conditions: Healthy Volunteers
Interventions: CC-220, Placebo; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Source: ClinicalTrials.gov public record

Updated Jan 12, 2014 · Synced May 22, 2026, 12:43 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Participants.

NCT06385119

View directory record Official record

Conditions: Healthy Participants
Interventions: Plixorafenib, Cobicistat; Drug
Lead sponsor: Fore Biotherapeutics; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Austin, Texas

Source: ClinicalTrials.gov public record

Updated Mar 26, 2026 · Synced May 22, 2026, 12:43 AM EDT

Terminated Phase 1Phase 2 Interventional Results available

Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies

NCT02629692

View directory record Official record

Conditions: Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)
Interventions: Vodobatinib (K0706) capsules; Drug
Lead sponsor: Sun Pharma Advanced Research Company Limited; Industry
Eligibility: 18 Years and older

Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 8
States / cities: Downey, California • Los Angeles, California • Jacksonville, Florida + 5 more

Source: ClinicalTrials.gov public record

Updated May 12, 2026 · Synced May 22, 2026, 12:43 AM EDT

Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Adult Male & Female Participants to Assess the Amount of the Study Medicine (SAR443820) Absorbed by the Body, When Given Orally in Fasted Condition as a Tablet Versus as a Capsule (Part 1) and When Given Orally as a Tablet in Fasted Condition Versus as a Tablet After Food (Part 2)

NCT05797701

View directory record Official record

Conditions: Amyotrophic Lateral Sclerosis (Healthy Volunteers)
Interventions: SAR443820; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years

Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Source: ClinicalTrials.gov public record

Updated Apr 3, 2023 · Synced May 22, 2026, 12:43 AM EDT